Role and significance of statins in the treatment of hypertensive patients

Current Medical Research and Opinion

Volumn 25, Issue 8, 2009, Pages 1995-2005

  Stepien, Mariusz ^a   Banach, Maciej ^a   Mikhailidis, Dimitri P ^b   Gluba, Anna ^a   Kjeldsen, Sverre E ^c   Rysz, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

Blood pressure; Hypertension; Statins; Treatment

Indexed keywords

AMLODIPINE; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; CERIVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOSARTAN; MEVINOLIN; PERINDOPRIL; PLACEBO; PRAVASTATIN; PROBUCOL; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; VALSARTAN;

BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DATA BASE; DRUG MECHANISM; DYSLIPIDEMIA; FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY DISEASE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROGNOSIS; PUBLICATION; REVIEW;

HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; TREATMENT OUTCOME;

EID: 67651027580     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903098081     Document Type: Review

References (59)

1. Koh KK, Quon MJ, Waclawiw MA. Are statins effective for simultaneously treating dyslipidemias and hypertension? Atherosclerosis 2008;196:1-8
2. Osende JI, Ruiz-Ortega M, Blanco-Colio LM, et al. Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study. Nephrol Dial Transplant 2004;19:528-31
3. Milionis HJ, Liberopoulos EN, Elisaf MS, et al. Analysis of antihypertensive effects of statins. Curr Hypertens Rep 2007; 9:175-83
4. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001;37:1450-7
5. Ferreira GA, Navarro TP, Telles RW, et al. Atorvastatin therapy improves endothelial-dependent vasodilatation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology 2007;46:1560-5
6. Susic D, Varagic J, Ahn J, et al. Beneficial pleiotropic vascular effects of rosuvastatin in two hypertensive models. Am J Coll Cardiol 2003;42:1091-7
7. Desjardins F, Sekkali B, Verreth W, et al. Rosuvastatin increases vascular endothelial PPAR(gamma) expression and corrects blond pressure variability in obese dyslipidemic mice. Eur Heart J 2008;29:128-37
8. Zhai Y, Gao X, Wu Q, et al. Fluvastatin decreases cardiac fibrosis possibly through regulation of TGF-β1/Smad 7 expression in the spontaneously hypertensive rats. Eur J Pharmacol 2008; 587:196-203
9. Terzoli L, Mircoli L, Raco R, et al. Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors. J Cardiovasc Pharmacol 2005;46:310-15
10. Strazullo P, Barbato A, Galletti F. Blood pressure reduction with statins: a metaanalysis of randomized controlled trials. J Hypertens 2006;24:S151
11. Stazullo P, Kerry SM, Barbato A, et al. Do statins reduce blood pressure? A meta-analysis of randomized controlled trials. Hypertension 2007;49:792-8
12. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol 2002; 39:1021-5
13. Leibovitz E, Hazanov N, Zimlichman R, et al. Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia. Am J Hypertens 2004;14 (Pt 1):1096-8
14. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension 1999;34:1281-6
15. Ikeda T, Sakurai J, Nakayama D, et al. Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am J Hypertens 2004; 17:502-6
16. Sposito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999;83:1497-9
17. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004;110: 3687-92
18. Koh KK, Quon MJ, Han SH, et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 2005;45:1088-93
19. Borghi C, Prandin MG, Costa FV, et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 2000; 35:549-55
20. Fogari R, Preti P, Zoppi A, et al. Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. Eur J Clin Pharmacol 2006;62:817-22
21. Kansui Y, Fuji K, Goto K, et al. Chronic fluvastatin treatment alters vascular contraction by inhibiting the Rho/Rho-kinase pathway. Clin Exp Pharmacol Physiol 2006;33:673-8
22. Wierzbicki AS. Statins and hypertension. J Hum Hypertens 2006;20:554-6
23. Agarwal R. Effects of statins on renal function. Mayo Clin Proc 2007;82:1381-90
24. Athyros VG, Elisaf M, Papageorgiou AA, et al.; GREACE Study Collaborative Group. The effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99
25. Collins R, Armitage J, Parish S, et al.; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003; 361:2005-16
26. Pereira AC, Sposito AC, Mota GF, et al. Endothelial nitric oxide synthase gene variant modulates the relationship between serum cholesterol levels and blood pressure in the general population: new evidence for a direct effect of lipids in arterial blood pressure. Atherosclerosis 2006;184:193-200
27. Golomb BA, Ritchie JB, Criqui MH, et al. Statins lower blood pressure: results from the UCSD statin study. Circulation 2004;110(Suppl III): III-402
28. Borghi C, Dormi A, Veronesi M, et al.; Brisighella Heart Study Working Party. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella heart Study. Am Heart J 2004;148:285-92
29. Tjugen TB, Halvorsen S, Bjřrnerheim R, et al. The role of statins in patients with arterial hypertension. Arch Med Sci 2007; 3:S99-103
30. Sever PS, Poulter NR, Dahlof B, et al.; on behalf of the ASCOT Investigators. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extender observations 2 years after trial closure. Eur Heart J 2008;29:499-509
31. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007
32. Dahlof B, Sever PS, Poulter NR, et al., ASCOT Investigators. Prevention of cardiovascular events with antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906
33. Sever PS, Dahlöf B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:1149-58
34. Messerli FH, Pinto L, Tang S. Does the presence of hypertension affect cardiovascular benefits of statin therapy? Results from a meta-regression analysis of 69,984 patients. J Hypertens 2006;24(Suppl 4):S151
35. Foody JM, Joyce AT, Rudolph AE, et al. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Clin Ther 2008;30:195-205
36. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomized placebo controlled trial. Lancet 2002;360:7-22
37. Shepherd J, Blauw GJ, Murphy MB, et al.; PROSPER study group, PROspective Study of Pravastatin in the Elderly at Risk. Prospective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360:1623-30
38. Calhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004;364:685-96
39. Golomb BA, Criqui MH, White HL, et al. The UCSD Statin Study: a randomized controlled trial assessing the impact of statins on selected on selected noncardiac outcomes. Controlled Clin Trials 2004;25:178-202
40. Paraskevas KI, Hamilton G, Cross JM, et al. Atherosclerotic renal artery stenosis: association with emerging vascular risk factors. Nephron Clin Pract 2008;108:c56-66
41. Messerli FH, Pinto L, Tang SS, et al. Impact of systemic hypertension on the cardiovascular benefits of statin therapy - a meta-analysis. Am J Cardiol 2008;101:319-25
42. Höfer J, Niebauer J. Cardiovascular risk factors: lipids and life-style changes. Arch Med Sci 2007;3:S69-73
43. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al.; GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004;18:781-8
44. Irzmanski R, Barylski M, Banach M, et al. The concentration of atrial and brain natriuretic peptide in patients with idiopathic hypertension. Med Sci Monit 2007;13:CR449-56
45. Wang CY, Liao JK. Current advances in statin treatment: from molecular mechanisms to clinical practice. Arch Med Sci 2007;3:S91-6
46. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004;57:728-34
47. Irzmanski R, Banach M, Piechota M, et al. Atrial and brain natriuretic peptide and endothelin-1 concentration in patients with idiopathic arterial hypertension: the dependence on the selected morphological parameters. Clin Exp Hypertens 2007; 29:149-64
48. Kowalski J, Barylski M, Banach M, et al. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharmacol 2006;48:143-7
49. Goch A, Banach M, Mikhailidis DP, et al. Endothelial dysfunction in patients with noncomplicated and complicated hypertension. Clin Exp Hypertens 2009;31:20-30
50. Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-27
51. Milionis HJ, Liberopoulos EN, Achimastos A, et al. Statins: another class of antihypertensive agents? J Hum Hypertens 2006;20:320-35
52. Feldstein CA. Statins as antihypertensives. Recent Pat Cardiovasc Drug Discov 2008;3:92-7
53. Rajagopalan S, Zannad F, Radauceanu A, et al. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension. Am J Cardiol 2007;100:222-6
54. Tran D, Lowy A, Howes JB, et al. Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men. Diabetes Obes Metab 2005;7:273-81
55. Magen E, Viskoper R, Mishal J, et al. Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control. Isr Med Assoc J 2004;6:742-6
56. Refaat S, El-Ghaffar, El-Rahman Negm HA, et al. The role of aldosterone in myocardial dysfunction of Egyptian patients with essential hypertension. Arch Med Sci 2008;4:161-6
57. Banach M, Goch JH, Ugurlucan M, et al. Statins in the prevention of postoperative atrial fibrillation: is there really no effect? Am Heart J 2008;155:e53
58. Zanchetti A, Crepaldi G, Bond MG, et al. PHYLLIS Investigators. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS - a randomized double-blind trial. Stroke 2004;35:2807-12
59. Rysz J, Aronow WS, Stolarek RS, et al. Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 2009;13:541-50